Please use this identifier to cite or link to this item:
http://hdl.handle.net/1893/21506
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Newell, Michael | en_UK |
dc.contributor.author | Hunter, Angus | en_UK |
dc.contributor.author | Lawrence, Claire | en_UK |
dc.contributor.author | Tipton, Kevin | en_UK |
dc.contributor.author | Galloway, S D | en_UK |
dc.date.accessioned | 2017-06-08T23:16:50Z | - |
dc.date.available | 2017-06-08T23:16:50Z | - |
dc.date.issued | 2015-06 | en_UK |
dc.identifier.uri | http://hdl.handle.net/1893/21506 | - |
dc.description.abstract | In an investigator-blind, randomised cross-over design, male cyclists (mean±SD) age 34.0 (± 10.2) years, body mass 74.6 (±7.9) kg, stature 178.3 (±8.0) cm, peak power output (PPO) 393 (±36) W, and VO2max 62 (±9) ml·kg-1·min-1 training for >6h/wk for >3y (n=20) completed four experimental trials. Each trial consisted of a 2h constant load ride at 95% of lactate threshold (185 ± 25W) then a work-matched time trial task (~30min at 70% of PPO). Three commercially available carbohydrate (CHO) beverages, plus a control (water), were administered during the 2h ride providing 0, 20, 39 or 64g·h-1 of CHO at a fluid intake rate of 1L·h-1. Performance was assessed by time to complete the time trial task, mean power output sustained, and pacing strategy used. Mean task completion time (min:sec ± SD) for 39g·h-1 (34:19.5 ± 03:07.1, p=0.006) and 64g·h-1 (34:11.3 ± 03:08.5 p=0.004) of CHO were significantly faster than control (37:01.9 ± 05:35.0). The mean percentage improvement from control was -6.1% (95% CI: -11.3 to -1.0) and -6.5% (95% CI: -11.7 to -1.4) in the 39 and 64g·h-1 trials respectively. The 20g·h-1 (35:17.6 ± 04:16.3) treatment did not reach statistical significance compared to control (p = 0.126) despite a mean improvement of -3.7% (95% CI -8.8 to 1.5%). No further differences between CHO trials were reported. No interaction between CHO dose and pacing strategy occurred. 39 and 64g·h-1 of CHO were similarly effective at improving endurance cycling performance compared to a 0g·h-1 control in our trained cyclists. | en_UK |
dc.language.iso | en | en_UK |
dc.publisher | Human Kinetics | en_UK |
dc.relation | Newell M, Hunter A, Lawrence C, Tipton K & Galloway SD (2015) The Ingestion of 39 or 64 g·hr-1 of Carbohydrate is Equally Effective at Improving Endurance Exercise Performance in Cyclists. International Journal of Sport Nutrition and Exercise Metabolism, 25 (3), pp. 285-292. https://doi.org/10.1123/ijsnem.2014-0134 | en_UK |
dc.rights | Publisher allows this work to be made available in this repository. This article will be published in International Journal of Sport Nutrition and Exercise Metabolism by Human Kinetics: http://dx.doi.org/10.1123/ijsnem.2014-0134 | en_UK |
dc.subject | Nutrition | en_UK |
dc.subject | metabolism | en_UK |
dc.subject | Time trial | en_UK |
dc.title | The Ingestion of 39 or 64 g·hr-1 of Carbohydrate is Equally Effective at Improving Endurance Exercise Performance in Cyclists | en_UK |
dc.type | Journal Article | en_UK |
dc.identifier.doi | 10.1123/ijsnem.2014-0134 | en_UK |
dc.identifier.pmid | 25203688 | en_UK |
dc.citation.jtitle | International Journal of Sport Nutrition and Exercise Metabolism | en_UK |
dc.citation.issn | 1526-484X | en_UK |
dc.citation.volume | 25 | en_UK |
dc.citation.issue | 3 | en_UK |
dc.citation.spage | 285 | en_UK |
dc.citation.epage | 292 | en_UK |
dc.citation.publicationstatus | Published | en_UK |
dc.citation.peerreviewed | Refereed | en_UK |
dc.type.status | AM - Accepted Manuscript | en_UK |
dc.contributor.funder | GlaxoSmithKline | en_UK |
dc.author.email | s.d.r.galloway@stir.ac.uk | en_UK |
dc.citation.date | 31/08/2014 | en_UK |
dc.contributor.affiliation | University of Stirling | en_UK |
dc.contributor.affiliation | Sport | en_UK |
dc.contributor.affiliation | GlaxoSmithKline | en_UK |
dc.contributor.affiliation | Sport | en_UK |
dc.contributor.affiliation | Sport | en_UK |
dc.identifier.isi | WOS:000357661300008 | en_UK |
dc.identifier.scopusid | 2-s2.0-84940484853 | en_UK |
dc.identifier.wtid | 603638 | en_UK |
dc.contributor.orcid | 0000-0001-7562-6145 | en_UK |
dc.contributor.orcid | 0000-0002-6545-8122 | en_UK |
dc.contributor.orcid | 0000-0002-1622-3044 | en_UK |
dc.date.accepted | 2014-08-26 | en_UK |
dcterms.dateAccepted | 2014-08-26 | en_UK |
dc.date.filedepositdate | 2015-02-17 | en_UK |
dc.relation.funderproject | Carbohydrate dose-response study. | en_UK |
dc.relation.funderref | PO: 4086143 | en_UK |
rioxxterms.apc | not required | en_UK |
rioxxterms.type | Journal Article/Review | en_UK |
rioxxterms.version | AM | en_UK |
local.rioxx.author | Newell, Michael| | en_UK |
local.rioxx.author | Hunter, Angus|0000-0001-7562-6145 | en_UK |
local.rioxx.author | Lawrence, Claire| | en_UK |
local.rioxx.author | Tipton, Kevin|0000-0002-6545-8122 | en_UK |
local.rioxx.author | Galloway, S D|0000-0002-1622-3044 | en_UK |
local.rioxx.project | PO: 4086143|GlaxoSmithKline|http://dx.doi.org/10.13039/100004330 | en_UK |
local.rioxx.freetoreaddate | 2015-02-17 | en_UK |
local.rioxx.licence | http://www.rioxx.net/licenses/all-rights-reserved|2015-02-17| | en_UK |
local.rioxx.filename | Newell ML_ijsnem_2014-0134-in press.pdf | en_UK |
local.rioxx.filecount | 1 | en_UK |
local.rioxx.source | 1526-484X | en_UK |
Appears in Collections: | Faculty of Health Sciences and Sport Journal Articles |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Newell ML_ijsnem_2014-0134-in press.pdf | Fulltext - Accepted Version | 665.05 kB | Adobe PDF | View/Open |
This item is protected by original copyright |
Items in the Repository are protected by copyright, with all rights reserved, unless otherwise indicated.
The metadata of the records in the Repository are available under the CC0 public domain dedication: No Rights Reserved https://creativecommons.org/publicdomain/zero/1.0/
If you believe that any material held in STORRE infringes copyright, please contact library@stir.ac.uk providing details and we will remove the Work from public display in STORRE and investigate your claim.